A

Assertio Holdings Inc
NASDAQ:ASRT

Watchlist Manager
Assertio Holdings Inc
NASDAQ:ASRT
Watchlist
Price: 0.9408 USD -2.58% Market Closed
Market Cap: 89.7m USD
Have any thoughts about
Assertio Holdings Inc?
Write Note

Assertio Holdings Inc
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Assertio Holdings Inc
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
A
Assertio Holdings Inc
NASDAQ:ASRT
Total Other Income
$1.9m
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Total Other Income
-$195m
CAGR 3-Years
N/A
CAGR 5-Years
33%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Total Other Income
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Total Other Income
$1.1B
CAGR 3-Years
42%
CAGR 5-Years
205%
CAGR 10-Years
-1%
Eli Lilly and Co
NYSE:LLY
Total Other Income
$439.4m
CAGR 3-Years
-18%
CAGR 5-Years
8%
CAGR 10-Years
7%
No Stocks Found

Assertio Holdings Inc
Glance View

Market Cap
89.7m USD
Industry
Pharmaceuticals

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.

ASRT Intrinsic Value
1.5439 USD
Undervaluation 39%
Intrinsic Value
Price
A

See Also

What is Assertio Holdings Inc's Total Other Income?
Total Other Income
1.9m USD

Based on the financial report for Sep 30, 2024, Assertio Holdings Inc's Total Other Income amounts to 1.9m USD.

What is Assertio Holdings Inc's Total Other Income growth rate?
Total Other Income CAGR 3Y
-12%

Over the last year, the Total Other Income growth was 116%. The average annual Total Other Income growth rates for Assertio Holdings Inc have been -12% over the past three years .

Back to Top